Trial Profile
Effect of neoadjuvant buparlisib on PI3K/AKT/mTOR signaling pathway in PI3KCA mutated early breast cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2014
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary)
- Indications Early breast cancer
- Focus Adverse reactions; Pharmacodynamics
- 19 Dec 2014 New trial record